Skip to main content
Top
Published in: Current Hypertension Reports 5/2010

01-10-2010 | Clinical Trial Report

Optimal Blood Pressure for a Patient with Type 2 Diabetes Mellitus: Insight from the ACCORD Study

Authors: Matthew R. Weir, George L. Bakris

Published in: Current Hypertension Reports | Issue 5/2010

Login to get access

Excerpt

ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al.: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1575–1585. …
Literature
1.
go back to reference Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444.CrossRefPubMed Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434–444.CrossRefPubMed
2.
go back to reference ACCORD Study Group, Ginsberg HN, Elam MB, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563–1574. ACCORD Study Group, Ginsberg HN, Elam MB, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563–1574.
3.
go back to reference Sleight P, Redon J, Verdecchia P, et al.: Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009, 27:1360–1369.CrossRefPubMed Sleight P, Redon J, Verdecchia P, et al.: Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009, 27:1360–1369.CrossRefPubMed
4.
go back to reference Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805–2816.CrossRefPubMed Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805–2816.CrossRefPubMed
Metadata
Title
Optimal Blood Pressure for a Patient with Type 2 Diabetes Mellitus: Insight from the ACCORD Study
Authors
Matthew R. Weir
George L. Bakris
Publication date
01-10-2010
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 5/2010
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-010-0145-z

Other articles of this Issue 5/2010

Current Hypertension Reports 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine